Biology Reference
In-Depth Information
Overall, the protein biomarker discovery and
development
12. Anderson NL. The clinical plasma proteome: a survey
of clinical assays for proteins in plasma and serum.
Clin Chem
2010;
-
cantly and become an important part of bio-
medical research aimed at detecting diseases at
early stages, reducing the
field is projected to grow signifi-
(2):177
e
85.
13. Li J, Kelm KB, Tezak Z. Regulatory perspective on
translating proteomic biomarkers to clinical diagnos-
tics.
J Proteomics
2011;
56
financial burden on
healthcare and allowing for personalized medi-
cine approaches.
(12):2682
e
90.
14. Addona TA, Abbatiello SE, Schilling B, Skates SJ,
Mani DR, Bunk DM, et al. Multi-site assessment of the
precision and reproducibility of multiple reaction
monitoring-based measurements
74
of proteins
in
References
1. Legrain P, Aebersold R, Archakov A, Bairoch A,
Bala K, Beretta L, et al. The human proteome project:
current state and future direction.
Mol Cell Proteomics
2011;
(7):633
e
41.
15. Prakash A, Rezai T, Krastins B, Sarracino D,
Athanas M, Russo P, et al. Platform for establishing
interlaboratory reproducibility of selected reaction
monitoring-based mass spectrometry peptide assays.
J Proteome Res
2010;
plasma.
Nat Biotechnol
2009;
27
(7):M111.009993.
2. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C,
Okamoto A, et al. Identi
10
(12):6678
e
88.
16. Lopez MF, Rezai T, Sarracino DA, Prakash A,
Krastins B, Athanas M, et al. Selected reaction
monitoring-mass spectrometric immunoassay respon-
sive to parathyroid hormone and related variants.
Clin
Chem
2010;
9
cation by cDNA microarray
of genes involved in ovarian carcinogenesis.
Cancer
Res
2000;
(18):5007
e
11.
3. Anastasi E, Marchei GG, Viggiani V, Gennarini G,
Frati L, Reale MG. HE4: a new potential early
biomarker for the recurrence of ovarian cancer.
Tumour Biol
2010;
60
56
(2):281
e
90.
17.
Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma
proteomics.
Chem Rev
2007;
(8):3601
e
20.
18. Anderson NL, Anderson NG. The human plasma
proteome: history, character, and diagnostic prospects.
Mol Cell Proteomics
2002;
107
(2):113
e
9.
4. Hartwell L, Mankoff D, Paulovich A, Ramsey S,
Swisher E. Cancer biomarkers: a systems approach.
Nat Biotechnol
2006;
31
(11):845
e
67.
19. Domon B, Aebersold R. Mass spectrometry and
protein analysis.
Science
2006;
1
(8):905
e
8.
5. Wishart DS, Knox C, Guo AC, Eisner R, Young N,
Gautam B, et al. HMDB: a knowledgebase for the
human metabolome.
Nucleic Acids Res
2009;
24
(5771):212
e
7.
20. Zhao X, Barber-Singh J, Shippy SA. MALDI-TOF MS
detection of dilute, volume-limitedpeptide sampleswith
physiological salt levels.
Analyst
2004;
312
37
:
D603
e
10.
(9):817
e
22.
21. Sobhani K. Urine proteomic analysis: use of two-
dimensional
129
6.
Jensen ON. Modi
c proteomics: charac-
terization of post-translational modi
cation-speci
cations by mass
spectrometry.
Curr Opin Chem Biol
2004;
gel
electrophoresis,
isotope
coded
(1):33
e
41.
7. LandegrenU, Vanelid J, HammondM, NongRY,WuD,
Ulleras E, et al. Opportunities for sensitive plasma
proteome analysis.
Anal Chem
2012;
8
af
nity tags, and capillary electrophoresis.
Methods
Mol Biol
2009;
:325
e
46.
22. Dudley JT, Butte AJ. Identi
641
cation of discriminating
biomarkers for human disease using integrative
network biology.
Pac Symp Biocomput
; 2009:27
e
38.
23. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The
human urinary proteome contains more than 1500
proteins, including a large proportion of membrane
proteins.
Genome Biol
2006;
84
(4):1824
e
30.
8.
Schroder C, Jacob A, Tonack S, Radon TP, Sill M,
Zucknick M, et al. Dual-color proteomic pro
ling of
complex samples with a microarray of 810 cancer-
related antibodies.
Mol Cell Proteomics
2010;
9
(6):
1271
e
80.
9. Tabakman SM, Lau L, Robinson JT, Price J, Sherlock SP,
Wang H, et al. Plasmonic substrates for multiplexed
protein microarrays with femtomolar sensitivity and
broad dynamic range.
Nat Commun
2011;
(9):R80.
24. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization
of urinary biomarkers to creatinine during changes in
glomerular
7
filtration rate.
Kidney Int
2010;
78
(5):
:466.
10. Wu W, Slastad H, de la Rosa Carrillo D, Frey T,
Tjonnfjord G, Boretti E, et al. Antibody array analysis
with label-based detection and resolution of protein
size.
Mol Cell Proteomics
2009;
2
486
e
94.
25. Yamamoto T. The 4th Human Kidney and Urine
Proteome Project (HKUPP) workshop. 26 September
2009, Toronto.
Canada Proteomics
2010;
(11):2069
e
70.
26. Kuk C, Kulasingam V, Gunawardana CG, Smith CR,
Batruch I, Diamandis EP. Mining the ovarian cancer
ascites proteome
10
(2):245
e
57.
11. Picotti P, Aebersold R. Selected reaction monitoring-
based proteomics: work
8
ows, potential, pitfalls and
future directions.
Nat Meth
2012;
for potential
ovarian cancer
9
(6):555
e
66.
biomarkers.
Mol Cell Proteomics
2009;
8
(4):661
e
9.
Search WWH ::
Custom Search